BinaxNOW Test Accuracy: How to Interpret Your Results

The BinaxNOW rapid antigen test is highly reliable when it reads positive but less reliable when it reads negative, and that asymmetry is the single most important thing to understand when interpreting your result. Across large studies, its specificity (the ability to correctly identify people who are not infected) consistently lands above 98%, while its sensitivity (the ability to catch true infections) ranges widely, from about 65% to over 95%, depending on when you test, whether you have symptoms, and how much virus is in your nose. That gap between a trustworthy positive and a less trustworthy negative shapes every practical decision you make with this test.

Why Positives Are Almost Always Real

If your BinaxNOW shows two lines, you almost certainly have COVID-19. The test’s specificity hovers around 99% or higher across nearly every study that has evaluated it. In a large community testing site in Massachusetts, specificity hit 100% in symptomatic adults and children alike.¹ A Puerto Rico study of over 1,500 paired tests found specificity above 98% regardless of how many days had passed since symptoms began.² Even a broad review of lateral flow antigen tests across multiple brands reported overall specificity around 99.6%.³

The practical upshot: false positives on a properly performed BinaxNOW are rare. When they do happen, the cause is almost always a problem with how the test was run, not an inherent flaw in the test itself. Researchers found that skipping the kit’s buffer solution and applying the nasal sample directly to the test card produced false-positive signals that looked indistinguishable from true positives. The buffer maintains the right pH and salt balance for the antibodies on the test strip to work correctly; without it, nonspecific protein interactions generate a fake line.⁴ So if you followed the instructions and see a positive, trust it.

Why Negatives Need More Thought

A negative BinaxNOW result is not as definitive. Sensitivity varies enormously depending on the circumstances, which means the test misses a real fraction of infections. In one CDC evaluation at community testing sites in Arizona, sensitivity was only about 64% in symptomatic people and roughly 36% in asymptomatic people.⁵ Other studies have found considerably better numbers: about 84% overall sensitivity in Puerto Rico, and nearly 97% in newly symptomatic adults in Massachusetts.² ¹ The wide range tells you that the test’s ability to detect infection is not a fixed number; it shifts based on conditions that are largely within your control.

The underlying reason is straightforward. BinaxNOW detects viral protein (the nucleocapsid antigen), not genetic material. PCR tests amplify tiny traces of viral RNA billions of times over, so they can catch infections at extremely low viral loads. An antigen test cannot do that; it needs a threshold amount of viral protein sitting on the swab to trigger a visible line. When the amount of virus in your nose is high, the test performs beautifully. When it is low, the test often misses.

Timing Is the Biggest Factor in Accuracy

The most consistent finding across studies is that the BinaxNOW performs best during the first week of symptoms, and its accuracy drops sharply afterward. The Puerto Rico study found sensitivity of about 92% during days one through three after symptom onset and roughly 94% during days four through six, but it fell to around 70% at seven days or later.² A multi-assay evaluation confirmed this pattern: sensitivity during the first six days of symptoms reached 100% for most rapid antigen platforms when viral loads were high, while false-negative samples had an average symptom duration of over 11 days.⁶

This maps onto how the virus behaves in your body. Viral load in the nose typically peaks in the first few days around or just after symptom onset, then declines. The BinaxNOW’s sweet spot is that peak window. If you wait more than a week to test, a negative result means much less, because the virus may still be present at levels too low for the test to pick up, even though you could still be shedding enough to infect others or still be PCR-positive.

For people without symptoms who are testing after a known exposure, the timing calculus is trickier. Viral loads tend to be lower on average in asymptomatic people, and there is no symptom-onset clock to guide when to swab. That is why serial testing matters so much for this group.

Symptomatic Versus Asymptomatic Testing

Across nearly every evaluation, the BinaxNOW performs notably worse in people without symptoms. One study at a high-volume self-referred site found sensitivity of about 87% in symptomatic individuals versus roughly 71% in asymptomatic ones.⁷ The Massachusetts drive-through site data showed an even wider gap: about 70% sensitivity in asymptomatic adults and around 65% in asymptomatic children.¹

The explanation ties back to viral load. People with symptoms tend to have higher concentrations of virus in their nasal passages. In one university screening study, the median PCR cycle threshold for samples that the BinaxNOW correctly caught was around 17.6, compared to about 29.6 for samples the test missed. When cycle threshold values were below 23 (indicating high viral loads), agreement between the rapid test and PCR was about 96%.⁸ In the CDC Arizona evaluation, false-negative BinaxNOW results had median cycle threshold values of about 34, while true positives clustered around 22.⁵ In plain terms, if you are sick enough to feel it, the test is much more likely to catch you.

Serial Testing Closes the Accuracy Gap

A single rapid test is a snapshot. If the snapshot happens to catch you before viral load has peaked, you get a false negative. The fix is to test more than once. A study in U.S. correctional facilities showed exactly how dramatic the improvement can be. A single BinaxNOW test had about 67% sensitivity. Two tests bumped that to roughly 89%. Three tests over a short window pushed sensitivity to about 96%, with specificity staying above 98%.⁹

This is why the FDA-authorized instructions for at-home BinaxNOW testing recommend testing twice, 24 to 48 hours apart, especially when you have no symptoms. A single negative does not rule out infection. Two negatives spaced a day or two apart are substantially more reassuring, and three negatives over a few days approach the reliability of a single PCR test.

Self-Testing Versus Professional Collection

One common worry is that swabbing your own nose at home is less reliable than having a healthcare worker do it. The data on this are more reassuring than you might expect. A direct comparison found that self-administered BinaxNOW tests had roughly 84% sensitivity, while clinician-performed tests reached about 88%, and the difference was not statistically significant.¹⁰ Specificity was essentially identical for both groups. An earlier study did find a wider gap, with self-collected swabs showing lower sensitivity, but that study had a much smaller sample for the self-collected arm.¹¹

The bigger issue with home testing turned out to be reading the result, not collecting the sample. About 5% of positive results in the self-testing comparison were potentially missed because participants misread the card, not because the test itself failed to produce a line.¹⁰ A faint second line is still a positive. If you hold the card at a bad angle or in dim lighting, you could miss it. Reading your result in good lighting and looking carefully for any trace of a second line matters more than most people realize.

How the Test Performs in Children

Pediatric performance has been a sore spot. In a school-based evaluation, only about 56% of PCR-positive children also tested positive on BinaxNOW. Among symptomatic kids, concordance was around 64%, and among asymptomatic children it dropped to roughly 51%.¹² That is substantially lower than adult performance in most studies. However, when only children with high viral loads were considered (cycle threshold below 25), agreement jumped to about 94%, reinforcing that the test works well when enough virus is present.¹²

A later pediatric study during the Delta wave found much higher sensitivity, around 93%, and a negative predictive value above 99%.¹³ The authors speculated that the higher viral loads typical of Delta infections may have driven the improved detection. The takeaway for parents: a positive BinaxNOW in a child is reliable, but a single negative in a child with known exposure deserves a repeat test or confirmation with PCR.

Do Variants Affect the Test

Because BinaxNOW targets the nucleocapsid protein rather than the spike protein, it has been more resilient to variant-driven changes than some observers feared. Lab testing confirmed that BinaxNOW successfully detected Alpha, Beta, Gamma, Delta (including subtypes with different nucleocapsid mutations), Lambda, Mu, Eta, and Omicron variants, all at comparable sensitivity within the clinically relevant range.¹⁴ There was a signal that Omicron detection required somewhat higher viral concentrations than other variants, meaning the test’s detection ceiling was slightly lower for Omicron.¹⁴ In practice, this means the advice to test early and test more than once became even more relevant during Omicron waves.

Nasal Swabs Versus Throat Swabs

During the Omicron surge, there was a wave of anecdotal advice suggesting you should swab your throat instead of your nose. The data do not support switching. In a direct comparison during Omicron, nasal BinaxNOW swabs detected about 86% of PCR-positive cases with meaningful viral loads (cycle threshold below 30), while throat swabs detected only about 47%.¹⁵ Combining both swab sites (nasal plus throat) bumped detection to about 90%, a modest gain over nasal alone.¹⁵ The BinaxNOW was designed and validated for nasal swabs, and the buffer chemistry is optimized for nasal mucus. Using it on a throat swab alone cuts your detection rate roughly in half.

What About Expired Tests

Many people accumulated boxes of BinaxNOW during the pandemic and now wonder whether expired kits still work. Lab testing found that expired tests performed nearly as well as fresh ones. At the test’s limit of detection, both expired and unexpired kits showed 100% sensitivity. At ten times that concentration, unexpired kits held at 100% while expired kits came in at about 99%, a statistically insignificant difference. The one notable difference was that expired tests produced fainter lines at every viral concentration.¹⁶ So an expired kit is still useful in a pinch, but read the result even more carefully than usual, since the positive line may be subtler than on a fresh test. Abbott has also periodically extended expiration dates for specific lot numbers, so check the FDA’s website for your lot before discarding a box.

Does a Positive BinaxNOW Mean You Are Contagious

This is probably the question people care about most, and the answer is less clean than you want it to be. A positive antigen test does correlate with higher viral loads, and higher viral loads correlate with infectiousness. But the relationship is not perfectly tight. One study that compared daily BinaxNOW results against viral culture (the gold standard for whether live, replicating virus is present) found the rapid test’s sensitivity for predicting a positive culture was only about 44%.¹⁷ The negative predictive value was much better, around 91%, meaning a negative rapid test was a reasonably good sign that you were no longer growing live virus.¹⁷

In practical terms, a positive BinaxNOW at any point in your infection is a strong reason to act as if you are contagious. A negative test late in your illness is a reasonable (though imperfect) signal that you are becoming less infectious. Modeling work has suggested that using rapid antigen tests to guide the end of isolation, rather than relying on a fixed number of days alone, could substantially reduce secondary infections. One analysis found that antigen testing on day six of isolation brought predicted secondary infections down to about 3 per 100 people, compared to roughly 23 per 100 with a flat five-day isolation and no test.¹⁸

The Population-Level Math Behind Rapid Testing

One reason public health authorities pushed rapid antigen testing so hard, despite its lower sensitivity compared to PCR, is that speed and frequency can outweigh raw accuracy. A PCR test that takes two days to come back catches more infections per swab, but the delay means infected people keep spreading virus while waiting. A BinaxNOW that misses some infections but gives you an answer in 15 minutes lets you isolate immediately when positive. Modeling estimated that making rapid tests available on a weekly basis across the U.S. could avert roughly 2.8 million infections and about 15,700 deaths over a 60-day period, at a cost of around $7,900 per infection prevented.¹⁹ A European analysis similarly found population-wide rapid testing to be cost-effective under a range of transmission scenarios.²⁰ The imperfect sensitivity of any single test matters far less when people test repeatedly and act on results quickly.

1
PubMed Central. Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts
2
PubMed Central. Diagnostic Accuracy of the Abbott BinaxNOW COVID‐19 Antigen Card Test, Puerto Rico
3
Nature Reviews Bioengineering. Lateral flow test engineering and lessons learned from COVID-19
4
PubMed Central. Generation of False-Positive SARS-CoV-2 Antigen Results with Testing Conditions outside Manufacturer Recommendations: A Scientific Approach to Pandemic Misinformation
5
Morbidity and Mortality Weekly Report. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020
6
PubMed Central. Time scale performance of rapid antigen testing for SARS-CoV-2: Evaluation of 10 rapid antigen assays
7
PubMed Central. Implementation and Accuracy of BinaxNOW Rapid Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a High-Volume Self-Referred Testing Site
8
PubMed Central. Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting
9
PubMed Central. Testing Frequency Matters | An Evaluation of the Diagnostic Performance of a SARS-CoV-2 Rapid Antigen Test in United States Correctional Facilities
10
PubMed Central. Self-administered versus clinician-performed BinaxNOW COVID rapid test: a comparison of accuracy
11
Scientific Reports. Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration
12
PLOS ONE. Evaluation of the Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection in children: Implications for screening in a school setting
13
PubMed Central. High Sensitivity and NPV for BinaxNOW Rapid Antigen Test in Children at a Mass Testing Site during Prevalent Delta Variant Period
14
iScience. Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern
15
PubMed Central. Comparison of SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction and BinaxNOW Rapid Antigen Tests at a Community Site During an Omicron Surge: A Cross-Sectional Study
16
PubMed Central. Accuracy of Expired BinaxNOW Rapid Antigen Tests
17
PubMed Central. Daily, self-test rapid antigen test to assess SARS-CoV-2 viability in de-isolation of patients with COVID-19
18
PubMed Central. Cost-effectiveness of antigen testing for ending COVID-19 isolation
19
PubMed Central. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission
20
PubMed Central. Assessment of a SARS-CoV-2 population-wide rapid antigen testing in Italy: a modeling and economic analysis study